Want to see HK:2607 full AI Analyst Report?
Shanghai Pharmaceuticals Holding Co (2607) AI Stock Analysis
Shanghai Pharmaceuticals Holding Co
(HKEX:2607)
The score is driven primarily by financial performance: strong TTM revenue growth is offset by thin and weakening margins, declining ROE, and volatile free cash flow. Valuation is a clear positive with a moderate P/E and high dividend yield, while technicals are neutral-to-slightly weak given price sitting below longer-term moving averages and muted momentum signals.
Shanghai Pharmaceuticals Holding Co (2607) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 8.46B
- Dividend Yield
- 5.88%
- Average Volume (3M)
- 1.66M
- Price to Earnings (P/E)
- 11.9
- Beta (1Y)
- 0.37
- Revenue Growth
- 9.12%
- EPS Growth
- -3.22%
- Country
- Hong Kong
- Employees
- 49,608
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Distribution
Shanghai Pharmaceuticals Holding Co Business Overview & Revenue Model
Company Description
Shanghai Pharmaceuticals Holding Co., Ltd., an investment holding company based in Shanghai, People's Republic of China, maintains a robust presence across the pharmaceutical and healthcare industries. Its core activities involve the research, develo...
Shanghai Pharmaceuticals Holding Co Financial Statement Overview
Summary
TTM revenue growth is very strong (~70%), but profitability is thin and has softened (net margin ~1.8% vs ~2.0% in 2025; EBIT margin ~3.2% vs ~4.1%). Leverage is moderate but rising (debt-to-equity ~0.75), ROE has trended down (~6.6% TTM vs ~10.3% in 2021), and cash generation is positive yet volatile with structurally low cash flow relative to sales (OCF ~3–4% of revenue).
Income Statement
64PositiveBalance Sheet
62PositiveCash Flow
55Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 290.47B | 283.58B | 275.25B | 260.30B | 231.98B | 215.82B |
| Gross Profit | 30.89B | 30.42B | 30.63B | 30.93B | 30.49B | 28.54B |
| EBITDA | 12.57B | 14.37B | 12.06B | 10.90B | 12.44B | 10.55B |
| Net Income | 5.14B | 5.72B | 4.55B | 3.77B | 5.62B | 5.09B |
Balance Sheet | ||||||
| Total Assets | 241.92B | 233.15B | 221.21B | 211.97B | 198.13B | 163.44B |
| Cash, Cash Equivalents and Short-Term Investments | 42.23B | 43.08B | 44.38B | 40.67B | 37.01B | 22.39B |
| Total Debt | 59.09B | 49.48B | 47.79B | 42.90B | 38.56B | 31.69B |
| Total Liabilities | 148.04B | 143.36B | 137.47B | 131.65B | 120.13B | 104.37B |
| Stockholders Equity | 79.30B | 75.89B | 71.68B | 68.52B | 67.06B | 49.36B |
Cash Flow | ||||||
| Free Cash Flow | 7.22B | 3.83B | 3.43B | 2.26B | 2.06B | 942.55M |
| Operating Cash Flow | 9.50B | 6.15B | 5.83B | 5.23B | 4.74B | 5.06B |
| Investing Cash Flow | -3.14B | -3.98B | 415.98M | -2.49B | -12.47B | -6.02B |
| Financing Cash Flow | -10.64B | -5.65B | -1.86B | 231.85M | 12.14B | 1.57B |
Shanghai Pharmaceuticals Holding Co Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2607, the sentiment is Positive. The current price of 11.11 is above the 20-day moving average (MA) of 11.05, above the 50-day MA of 11.11, and below the 200-day MA of 11.26, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 51.11 is Neutral, neither overbought nor oversold. The STOCH value of 37.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2607.
Shanghai Pharmaceuticals Holding Co Peers Comparison
Overall Rating
HK:219281Outperform
HK:109965Neutral- HK:260763Neutral
HK:228947Neutral
HK:067337Underperform
HK:193126Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2192 | 81Outperform | HKD 4.67B | 11.63 | 7.05% | 4.98% | 6.47% | 8.10% |
| HK:1099 | 65Neutral | HKD 50.52B | 6.11 | 8.33% | 4.88% | 2.78% | 7.71% |
| HK:2607 | 63Neutral | HKD 64.52B | 11.88 | 6.64% | 5.88% | 9.12% | -3.22% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:2289 | 47Neutral | HKD 592.92M | 10.83 | 7.70% | 6.26% | 14.25% | 0.83% |
| HK:0673 | 37Underperform | HKD 360.66M | -5.29 | -273.18% | ― | 5.52% | 56.54% |
| HK:1931 | 26Underperform | HKD 575.63M | -6.46 | -2.60% | ― | -2.55% | -145.60% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2607 | Shanghai Pharmaceuticals Holding Co Class H | 11.11 | -0.06 | -0.53% | |
| HK:0673 | China Health Group | 0.26 | -0.36 | -58.06% | |
| HK:1099 | Sinopharm Group Co Class H | 16.19 | -2.17 | -11.84% | |
| HK:1931 | IVD Medical Holding Limited | 0.35 | -5.93 | -94.35% | |
| HK:2192 | Medlive Technology Co., Ltd. | 6.30 | -4.03 | -38.99% | |
| HK:2289 | Charmacy Pharmaceutical Co., Ltd. Class H | 5.49 | 0.38 | 7.46% |
Shanghai Pharmaceuticals Holding Co Corporate Events
Shanghai Pharmaceuticals Issues Unaudited 2026 Third-Quarter Report With Board Assurance
Shanghai Pharmaceuticals Holding Co., Ltd. has released its unaudited third quarterly report for 2026, prepared under PRC Accounting Standards for Business Enterprises, in compliance with Hong Kong securities disclosure rules. The board, senior manag...
Shanghai Pharmaceuticals Renews Packaging Deal with Wing Fat Printing
Shanghai Pharmaceuticals Holding Co., Ltd. has renewed its procurement framework agreement with Wing Fat Printing for the period from 1 January 2027 to 31 December 2027. Under the agreement, Wing Fat Group will continue to supply printed packaging ma...
Shanghai Pharmaceuticals Renews Three-Year Connected Property Leasing Deal
Shanghai Pharmaceuticals Holding has renewed a three-year property leasing framework agreement with its controlling shareholder, Shanghai Pharmaceutical (Group), under which the group will continue to lease properties from 1 January 2027 to 31 Decemb...
Shanghai Pharmaceuticals Sets Board Meeting to Approve Third-Quarter Results
Shanghai Pharmaceuticals Holding Co., Ltd. has announced that its board will convene on 29 October 2026 to review and approve the group’s third-quarter results for the nine months ended 30 September 2026. The meeting will also clear the way for...
Shanghai Pharmaceuticals Updates Interim Dividend and Tax Details for H Shareholders
Shanghai Pharmaceuticals Holding has declared an interim ordinary cash dividend of RMB 1 per 10 shares for the six months ended 30 June 2026, equivalent to HKD 1.1663 per 10 shares for H shareholders, with the ex-dividend date set for 16 September 20...
Shanghai Pharmaceuticals Sets Record Date and Tax Terms for 2026 Interim Dividend
Shanghai Pharmaceuticals Holding Co., Ltd. has confirmed the record date and payment arrangements for its interim cash dividend for the first half of 2026, declaring RMB1.00 (tax inclusive) for every ten shares. The dividend will be paid on 23 Octobe...
Shanghai Pharmaceuticals Posts Strong H1 2026 Profit and Declares Cash Dividend
Shanghai Pharmaceuticals Holding Co. has released its unaudited interim results for the six months ended 30 June 2026, prepared under Chinese Accounting Standards and reviewed by its board and audit committee. The company’s leadership has colle...
Shanghai Pharmaceuticals Announces Interim Cash Dividend for First Half of 2026
Shanghai Pharmaceuticals Holding Co., Ltd. has announced an interim ordinary cash dividend for the six months ended 30 June 2026, declaring a payout of RMB 1 per 10 shares for the financial year ending 31 December 2026. Key operational dates for Hong...
Shanghai Pharmaceuticals Sets Board Meeting to Approve 2026 Interim Results and Consider Dividend
Shanghai Pharmaceuticals Holding Co. has scheduled a board meeting for 27 August 2026 to review and approve the interim results for the six months ended 30 June 2026, covering the performance of the company and its subsidiaries. The board will also c...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 31, 2026